Herein we describe the case of a patient with advanced, recurrent metastatic pancreatic cancer who—after exhausting 3 lines of standard therapy—achieved a complete response with the combination of N-803, PD-L1 t-haNK, aldoxorubicin, and a single dose of CEA- and MUC-based adeno (Ad5) vaccines. This evidence concerns the gene CD274 and familial pancreatic carcinoma.